SpringWorks Therapeutics Stock (NASDAQ: SWTX)

SpringWorks Therapeutics (NASDAQ:SWTX) Stock

SPRINGWORKS THERAPEUTICS INC

SpringWorks Therapeutics

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics Inc

WIIM

TIC stock has given up its prior gain. Acuren shares were trading higher after the company announced a merger with NV. Also, the company announced it has been approved for uplisting to the NYSE.

Sylogist (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SYZ#TSX">SYZ</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.08 by 150 percent. This is a 81.82 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $16.32 million which missed the analyst consensus estimate of $16.34 million by 0.11 percent. This is a 0.10 percent increase over sales of $16.31 million the same period last year.

Earnings

Earnings Misses

News

TSX:SYZ

Sylogist Q1 GAAP EPS $(0.04) Misses $0.08 Estimate, Sales $16.32M Miss $16.34M Estimate

Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) shares are rising on the heels of the company&#8217;s better-than-expected quarterly results. Several analysts raised price targets following the report. Here&#8217;s a look at <a href="https://www.benzinga.com/news/earnings/25/05/45422303/cisco-shares-climb-after-q3-eps-revenue-beat-estimates-details">what&#8217;s going on</a>.
What To Know: Cisco reported fiscal third-quarter results that came in above analyst expectations. The company said it&#8217;s seeing &#8220;clear demand&#8221; for its technologies driven by momentum with AI, which is being fueled by its secure networking portfolio and global partnerships. 
<ul class="wp-block-list">
<li>Q3 Revenue: $14.15 billion, versus estimates of $14.08 billion</li>
</ul>
<ul class="wp-block-list">
<li>Q3 Adjusted EPS: 96 cents, versus estimates of 92 cents</li>
</ul>
&#8220;Another quarter of solid execution in&nbsp;Q3&nbsp;drove revenue, margins and EPS above our&nbsp;guidance&nbsp;ranges. Our innovation positions us well for future growth and our operational discipline is generating strong cash flows, enabling us to deliver significant shareholder returns,&#8221; said&nbsp;Scott Herren, CFO of Cisco. 
Cisco guided for fourth-quarter revenue of $14.5 billion to $14.7 billion versus estimates of $14.58 billion, and adjusted earnings of 96 cents to 98 cents per share versus estimates of 95 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Cisco also raised its full-year revenue guidance from a range of $56 to $56.5 billion to a new range of $56.5 to $57 billion, and bumped up its full-year adjusted earnings forecast from $3.68 to $3.74 to a new range of $3.77 to $3.79. Analysts are anticipating full-year revenue of $56.47 billion and full-year adjusted earnings of $3.73 per share. 
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/05/45430485/cisco-is-targeting-a-multi-billion-dollar-security-shake-up-and-it-starts-with-killing-the-firewall">Cisco Is Targeting A Multi-Billion-Dollar Security Shake-Up—And It Starts With Killing The Firewall</a>
Analyst Changes: Following the print, multiple analysts lifted price targets on the stock. 
<ul class="wp-block-list">
<li>Wells Fargo analyst Aaron Rakers upgraded Cisco from Equal-Weight to <a href="https://www.benzinga.com/analyst-stock-ratings">Overweight</a> and raised the price target from&nbsp;$72&nbsp;to&nbsp;$75.</li>
</ul>
<ul class="wp-block-list">
<li>Rosenblatt analyst Mike Genovese maintained a Buy rating and raised the price target from&nbsp;$63&nbsp;to&nbsp;$74.</li>
</ul>
<ul class="wp-block-list">
<li>JPMorgan analyst Samik Chatterjee maintained an Overweight rating and raised the price target from&nbsp;$70&nbsp;to&nbsp;$73.</li>
</ul>
<ul class="wp-block-list">
<li>Barclays analyst Tim Long maintained an Equal-Weight rating and raised the price target from&nbsp;$61&nbsp;to&nbsp;$66.</li>
</ul>
CSCO Price Action: <a href="http://benzinga.com/quote/csco">Cisco shares</a> are up year-to-date, but are still trading below 52-week highs of $66.50 reached in February. The stock was up 5.39% at $64.60 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">Tariffs Slow Retail Spending As Producer Prices Post Sharpest Drop Since 2020</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/MacroEcon">MacroEcon</a>/Shutterstock.

Guidance

Price Target

Movers

CSCO

Cisco Systems Stock Is Rising Thursday: What's Fueling The Move?

UBS analyst Kevin Caliendo maintains ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) with a Neutral and lowers the price target from $16 to $10.

Analyst Ratings

ZIMV

UBS Maintains Neutral on ZimVie, Lowers Price Target to $10

JMP Securities analyst Silvan Tuerkcan reiterates Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) with a Market Outperform and maintains $9 price target.

Reiteration

FHTX

JMP Securities Reiterates Market Outperform on Foghorn Therapeutics, Maintains $9 Price Target

UBS analyst Alberto Valerio maintains Controladora Vuela (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) with a Buy and lowers the price target from $12 to $6.

VLRS

UBS Maintains Buy on Controladora Vuela, Lowers Price Target to $6

Trading Ideas

New Fortress Energy Shares Resume Trade

UBS analyst Shneur Gershuni maintains Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Buy and lowers the price target from $259 to $228.

TRGP

UBS Maintains Buy on Targa Resources, Lowers Price Target to $228

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently rotating near our 585.75 reference level. For buyers to maintain control, we&#8217;d like to see price move up to 587.31 and establish that level as a support base. Should bulls remain dominant, the next upside objective is 589.71. Holding 589.71 during regular trading could open the door to a further move toward 592.00. If momentum remains on the buyers&#8217; side, the high bull objective for the day is marked at 593.73.&nbsp;
If 585.75 loses footing as a support area, we'll be watching 584.68 as the next key level to monitor. If pressure builds and sellers stay active, the downside may extend to 583.18. A breakdown beneath that could lead to further weakness toward 581.97. Should sentiment shift dramatically to the downside, the low bear objective on the day stands at 580.67.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is currently hovering near our level of 516.58. Bulls need to gain ground above 517.97 and solidify that area as a stable base. A firm hold could lead to a challenge of 518.65, and if strength persists, 519.87 may come into play. Should buyers stay aggressive, we anticipate a possible extension to 521.15. The top-side goal for bulls today is set at 522.57.&nbsp;
If the auction struggles to stay buoyant above 516.58, sellers may drive the price toward 515.00. Breaking below that level could invite further downside exploration to 513.64. A sustained bearish session may bring 511.53 into play, and if that floor fails to hold, we are targeting 509.87 as the session's lower bear target.
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
Apple is trading close to our level of 209.81. If bulls want to take charge, they'll need to secure 211.12 and convert it into a platform for higher prices. Holding that zone may propel the stock toward 212.44. Continued strength in the name could push price to 214.07, with the high-side bull objective standing at 215.25.&nbsp;
Should 209.81 fall through, we'll look to 208.81 for initial support. If sellers persist, a test of 207.93 could follow. Continued downward action may lead to 207.18 being probed, and if pressure intensifies further, our low bear target sits at 206.55.
Microsoft Corp. (MSFT)
Microsoft is currently trading near 450.26. If bulls are able to hold this area and drive price higher, the next upside target is 453.02. A clean move above and hold of this level during market hours could bring 455.77 into view. If bullish energy sustains, the upper boundary we're eyeing for today is 457.25.&nbsp;
On the downside, if 450.26 can't hold up, expect bears to aim for 448.18. A breakdown there could see the stock testing 446.33, with pressure building into 444.95 if sellers stay committed. Should the auction extend to deeper lows, the low bear target is marked at 442.95.
NVIDIA Corporation (NVDA)
NVIDIA is actively trading near 134.56. A bullish continuation would require price to push above 135.64 and turn it into a support floor. If that transition occurs, look for 136.98 to be challenged next. A healthy bid could bring price action to 137.94, with bulls aiming for a top-side target at 138.55.&nbsp;
If the bulls can't keep 134.56 intact, we expect the bears to pressure the stock lower toward 133.31. Failing that level could invite sellers to test 132.19. If momentum remains with the bears, 131.42 could be visited, and the session's low-side bear target is placed at 129.53.
Alphabet Inc Class A (GOOGL)
Alphabet is currently auctioning near 163.79. For bulls to stay in control, they need to establish 165.41 as a solid base and push toward 167.04. A sustained rally today could push price toward our upside objective of 169.34.&nbsp;
If 163.79 fails to act as support, the next area of interest lies at 161.79. A break below there may see the auction retreat to 160.36. Continued weakness could send the name down to our low-end target of 158.54.
Meta Platforms Inc (META)
Meta is auctioning near our level of 650.56. Bulls will want to maintain strength above this area and attempt a move to 655.54. If the momentum holds, the price may rally to 658.86. Should buyers remain in control, our high bull target of 663.33 becomes the key upside marker.&nbsp;
Should 650.56 give out, the first line of defense for the bulls is at 646.48. Selling pressure below that level could drag the price down to 642.59. If sellers remain dominant, the lower target for the day is 635.49.
Tesla Inc. (TSLA)
Tesla is currently revolving around 340.97. For a bullish day, price needs to climb toward 346.64 and hold it as firm support. If momentum follows through, the next step is 350.87. With sustained buying, 356.80 becomes the next potential area of interest. The bullish stretch target sits at 363.84.&nbsp;
If 340.97 doesn't hold, we'll be eyeing 333.93 as the next level under pressure. A breakdown through that opens the path to 327.59. If selling intensifies, 322.52 becomes the likely bear target to the downside.
Final Word:&nbsp;
Today's session is packed with market-moving data. At 8:30AM ET, we'll see the release of April's PPI Final Demand along with Initial and Continuing Jobless Claims. Also hitting the tape at that time are the Philly Fed Manufacturing Index and Empire State Manufacturing Survey—both key sentiment indicators. At 9:15AM ET, attention shifts to Industrial Production, Capacity Utilization, and Manufacturing Output, all offering a deeper look into real economic activity. At 10AM ET, housing data comes into focus with the NAHB Housing Market Index.&nbsp;
Fed commentary also plays a major role today, with Chair Jerome Powell scheduled to speak at 8:40AM ET, followed by remarks from FOMC's Barr at 2:05PM ET. With inflation, labor, manufacturing, and housing data all hitting at once, combined with Fed commentary, the market may experience heightened volatility. Stay sharp, manage your risk, and be ready to adapt as the data unfolds.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Technicals

Opinion

Signals

AAPL

How To Trade SPY, Tech After Biggest Monthly PPI Drop Since Covid

UBS analyst Dennis Geiger maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Neutral and lowers the price target from $44 to $27.

JACK

UBS Maintains Neutral on Jack In The Box, Lowers Price Target to $27

JMP Securities analyst Silvan Tuerkcan reiterates Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Market Outperform and maintains $20 price target.

BNTC

JMP Securities Reiterates Market Outperform on Benitec Biopharma, Maintains $20 Price Target

"Stay buckled. It's just a question of whether the airbags come out now,"&nbsp; Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) chief Harvey Schwartz told <a href="https://www.bloomberg.com/news/videos/2025-04-17/bloomberg-open-interest-04-17-2025-video">Bloomberg</a> in an interview on April 17. While tariffs have turned&nbsp; jetliners around mid-air and slowed parcel traffic, Schwartz insists the real hazard is the uncertainty most observers cannot see.
His warning landed as the U.S. and China traded blows that lifted some levies to 145% and stretched supply chains well beyond breaking points for some manufacturers.
Don't Miss:
<ul class="wp-block-list">
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
<h2 class="wp-block-heading">Buckle Up For Whiplash</h2>
The trade scuffle's first casualty was aviation. Reuters reported that a<a href="https://www.reuters.com/business/aerospace-defense/boeing-jet-returns-us-china-victim-trumps-tariff-war-2025-04-20/"> $55 million Boeing 737 MAX</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) painted for Xiamen Airlines left Renton, Washington, on April 18 but returned to Seattle the next evening after a 125% duty made the deal financially unviable for the Chinese carrier.
On April 20, <a href="https://www.dhl.com/discover/en-sg/news/important-announcement-shipping-to-us">DHL said</a> it would halt business-to-consumer shipments over $800 to the U.S. due to new customs rules, effective April 21. Delays hit lower-value parcels too. After discussions with U.S. authorities,<a href="https://www.dhl.com/us-en/home/important-information/2025/shipments-to-the-united-states-with-a-customs-value-exceeding-usd-800.html"> DHL resumed shipments </a>soon after, following adjustments that eased processing of higher-value entries.
Policymakers see the stress, too. On April 22, the <a href="https://mediacenter.imf.org/news/imf-world-economic-outlook-presser/s/33be8aaf-2578-4d8f-a8fd-ae7f5516ad3f">International Monetary Fund</a> released its updated World Economic Outlook, lowering its 2025 global growth forecast to 2.8%—a 0.5 percentage point decrease from January.
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
IMF Chief Economist Pierre-Olivier Gourinchas <a href="https://www.youtube.com/watch?v=uXT-vsT1qxo">said</a> global trade growth could be "more than halved" to 1.7% in 2025 if tariffs persist. He also said the U.S. growth forecast was trimmed to 1.8%, citing heightened uncertainty.
History shows why the C-suite are skittish. The tariff volley that began in 2018 lopped roughly <a href="https://ers.usda.gov/sites/default/files/_laserfiche/publications/102980/ERR-304.pdf?v=13480#:~:text=From%20mid%2D2018%20to%20the,occurring%20for%20exports%20to%20China.">$1.7 billion </a>off U.S. quarterly farm exports within months—a reminder of how friction can slice revenue.&nbsp;
The S&amp;P 500 experienced significant intraday volatility on April 8. The index surged by 4.1% in early trading, only to reverse course and decline by 3% later in the day, closing down 1.6%.
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.&nbsp;
In a separate <a href="https://www.youtube.com/watch?v=PC5_6RHwc-U">Bloomberg</a> interview, Schwartz emphasized that while a recession is &#8220;certainly on the table,&#8221; it&#8217;s premature to make a definitive judgment. He highlighted that the primary concern isn&#8217;t just the tariffs themselves but the pervasive uncertainty they introduce, which stalls decision-making and chills economic activity.&nbsp;
Schwartz said that CEOs are shifting from growth strategies to contingency planning amid the volatility.&nbsp;
He stressed the importance of the U.S. and China finding a cooperative equilibrium to stabilize global trade, warning that prolonged tensions could have far-reaching implications beyond immediate market disruptions.
Read Next:
<ul class="wp-block-list">
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Carlyle CEO Harvey Schwartz Says 'Stay Buckled' Amid Market Turmoil – 'It's Just A Question Of Whether The Airbags Come Out

UBS analyst Eliana Merle maintains Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) with a Buy and lowers the price target from $74 to $21.

ARVN

UBS Maintains Buy on Arvinas, Lowers Price Target to $21

JMP Securities analyst Patrick Walravens reiterates Bandwidth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAND#NASDAQ">BAND</a>) with a Market Outperform and maintains $36 price target.

BAND

JMP Securities Reiterates Market Outperform on Bandwidth, Maintains $36 Price Target

UBS analyst Timothy Chiodo maintains Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) with a Neutral and raises the price target from $5.5 to $5.75.

RSKD

UBS Maintains Neutral on Riskified, Raises Price Target to $5.75

New Fortress Energy Shares Halted On Circuit Breaker To The Downside, Shares Now Down 47.5%

UBS analyst Chris Kuntarich maintains Ibotta (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) with a Neutral and raises the price target from $42 to $55.

IBTA

UBS Maintains Neutral on Ibotta, Raises Price Target to $55

<a href="https://www.kerrisdalecap.com/wp-content/uploads/2025/05/STX%E2%80%93Kerrisdale.pdf">https://www.kerrisdalecap.com/wp-content/uploads/2025/05/STX%E2%80%93Kerrisdale.pdf</a>

Watching Seagate Technology; Shares See Volume To The Upside, Karrisdale Capital Issues Report On Co

Stephens &amp; Co. analyst Steven Etoch reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and maintains $250 price target.

Stephens & Co. Reiterates Overweight on Steris, Maintains $250 Price Target

Back in 2009, Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) was a modest $5 billion chipmaker, overshadowed by Intel Corp's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) $90 billion dominance.
Fast forward 16 years and Nvidia's market cap has skyrocketed to $3.3 trillion &#8211; making it 35 times more valuable than Intel's $95 billion. This extraordinary surge reflects Nvidia's transformation from a niche graphics card producer to the beating heart of the AI revolution.
Its GPUs now power everything from data centers to autonomous vehicles, fueling investor enthusiasm and a massive re-rating.
Read Also: <a href="https://www.benzinga.com/25/05/45433051/jim-cramer-says-gulf-countries-will-become-the-largest-hyperscalers-in-the-world-following-ai-deals">Jim Cramer Says Gulf Countries Will Become &#8216;Largest Hyperscalers In The World&#8217; After Nvidia&#8217;s 18,000 Blackwell Chip Deal</a>
<h2 class="wp-block-heading">Valuation Dynamics: Growth Premium Vs. Legacy Drag</h2>
Nvidia's current P/E ratio of <a href="https://fullratio.com/stocks/nasdaq-nvda/pe-ratio">45.6</a>, though high by traditional standards, actually sits below its 10-year average of 52.6, signaling that investors still see room for growth. 
Its forward P/E of 31.4 and PEG ratio under two reinforce this bullish outlook.
Meanwhile, Intel struggles with a negative earnings yield and a sky-high forward P/E of 80, reflecting challenges in regaining its footing. 
Intel's dated product lineup and execution issues contrast sharply with Nvidia's innovation-led momentum.
<h2 class="wp-block-heading">Looking Ahead: Earnings, Expectations, And The Future Of Chips</h2>
With Nvidia's first quarter earnings due May 28, the market is watching closely for signs of sustained growth amid a recent 20% monthly pullback. 
For Intel, the road ahead looks steeper as it struggles to catch up in AI and advanced manufacturing.
Ultimately, the 35x valuation gap isn't just about current profits &#8211; it's a market verdict on which company is shaping the future of computing. For now, Nvidia continues to lead the charge.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45431776/jensen-huang-says-he-wouldnt-start-nvidia-again-if-he-were-30-calling-the-journey-too-much-despite-the-companys-massive-success">Jensen Huang Says He Wouldn&#8217;t Start Nvidia Again If He Were 30, Calling The Journey &#8216;Too Much&#8217; Despite the Company&#8217;s Massive Success</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Tech

INTC

NVDA

Nvidia Now Worth 35x Intel After 16-Year Surge And Valuation Gap Keeps Growing

Press Releases

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Health Care

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders

Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, RDUS, ALBT, BRDG on Behalf of Shareholders

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

Comments

SpringWorks Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL